Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q3 2023 |
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
HCA HOLDINGS INC | 27 | Q1 2022 | 6.2% |
ZIMMER HLDGS INC | 26 | Q2 2022 | 9.3% |
DANAHER CORPORATION | 26 | Q3 2022 | 5.6% |
NEUROCRINE BIOSCIENCES INC | 26 | Q4 2022 | 7.8% |
UNITEDHEALTH GROUP INC | 24 | Q3 2022 | 6.4% |
VERTEX PHARMACEUTICALS INC | 24 | Q3 2021 | 5.3% |
HUMANA INC | 22 | Q3 2022 | 6.6% |
BRISTOL-MYERS SQUIBB CO | 22 | Q3 2022 | 9.2% |
BIOGEN INC | 21 | Q3 2022 | 8.5% |
LABORATORY CORP AMER HLDGS | 20 | Q2 2020 | 8.3% |
View HealthCor Management, L.P.'s complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
CareView Communications Inc | May 26, 2023 | 186,970,000 | 32.0% |
Research Alliance Corp. IISold out | February 14, 2023 | 0 | 0.0% |
ARYA Sciences Acquisition Corp IVSold out | February 14, 2022 | 0 | 0.0% |
Aurinia Pharmaceuticals Inc.Sold out | February 14, 2022 | 0 | 0.0% |
MADRIGAL PHARMACEUTICALS, INC.Sold out | February 14, 2022 | 0 | 0.0% |
Medicus Sciences Acquisition Corp.Sold out | February 14, 2022 | 0 | 0.0% |
Arcturus Therapeutics Holdings Inc.Sold out | February 12, 2021 | 0 | 0.0% |
Intersect ENT, Inc.Sold out | February 12, 2021 | 0 | 0.0% |
NEVRO CORP | February 12, 2021 | 156,046 | 0.5% |
ViewRay, Inc.Sold out | February 12, 2021 | 0 | 0.0% |
View HealthCor Management, L.P.'s complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
4 | 2023-05-26 |
4 | 2023-05-26 |
SC 13D/A | 2023-05-26 |
4 | 2023-04-04 |
4 | 2023-04-04 |
SC 13D/A | 2023-04-03 |
13F-HR | 2023-02-15 |
SC 13G/A | 2023-02-14 |
4 | 2023-01-04 |
4 | 2023-01-04 |
View HealthCor Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.